Key result
SGLT-2 inhibitors reduce major cardiovascular events ~12% and improve renal outcomes in type 2 diabetes.
Why the study?
This updated meta-analysis evaluated cardiorenal outcomes of SGLT-2is available in Europe or the United States in patients with T2D.
Do sodium-glucose co-transporter-2 inhibitors reduce major adverse cardiovascular events and composite renal outcomes in patients with type 2 diabetes?
Meta-Analysis (n=65,587)
Do sodium-glucose co-transporter-2 inhibitors reduce major adverse cardiovascular events and composite renal outcomes in patients with type 2 diabetes?
Answers are grounded in this paper and cite their sources.
In patients with type 2 diabetes, SGLT-2 inhibitors provide a 12% reduction in major adverse cardiovascular events and a 39% reduction in composite renal outcomes regardless of baseline cardiovascular disease status.
A meta‐analysis of cardiorenal outcomes of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2is) available in Europe or the United States in patients with type 2 diabetes (T2D) is presented. An electronic search up to 6 January 2021 was conducted to determine eligible trials. A total of eight cardiorenal outcomes trials of SGLT‐2is (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin and sotagliflozin) were identified, with 65,587 patients. Data were analysed using a random effects model. Overall, SGLT‐2is were associated with a 12% reduced risk of major adverse cardiovascular events (MACE; HR = 0.88; 95% CI, 0.83–0.93; Q statistic, p = .19), with no significant heterogeneity ( p for interaction = .465) between subgroups of patients with or without cardiovascular disease (CVD). The risk of the composite renal outcome was significantly reduced by treatment with SGLT‐2is (HR = 0.61, 95% CI, 0.54–0.70), with no significant heterogeneity of associations with outcome (I 2 = 37%, p = .11), and no difference in the risk between patients with or without CVD ( p for interaction = .665). SGLT‐2is have moderate benefits on MACE and major benefits on the progression of diabetic kidney disease.
No takes yet. Share an insight, caveat, or question.
Giugliano et al. (2021) conducted a meta-analysis in Type 2 diabetes (n=65,587). Sodium-glucose co-transporter-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, and sotagliflozin) was evaluated on Major adverse cardiovascular events (MACE) (HR 0.88, 95% CI 0.83-0.93). SGLT-2 inhibitors reduced major adverse cardiovascular events by 12% and composite renal outcomes in type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: